^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MRTX1133

    i
    Company:
    BMS
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    Apply
    Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (NCT05737706)
    Phase 1/2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    11/21/2023
    Initiation :
    03/20/2023
    Primary completion :
    08/30/2026
    Completion :
    08/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    MRTX1133